Your browser doesn't support javascript.
loading
Increased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomas.
Dogan, B A; Tuna, M M; Arduç, A; Basaran, M N; Küçükler, K; Dagdelen, I; Berker, D; Güler, S.
Affiliation
  • Dogan BA; Endocrinology and Metabolism Disease, Darica Farabi State Hospital, Kocaeli, Turkey.
  • Tuna MM; Endocrinology and Metabolism Disease, Dicle University, Diyarbakir, Turkey.
  • Arduç A; Endocrine and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Diabetes, National Institutes of Health, Bethesda, Maryland, USA.
  • Basaran MN; Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey.
  • Küçükler K; Endocrinology and Metabolism Disease, Hitit University, Çorum, Turkey.
  • Dagdelen I; Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey.
  • Berker D; Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey.
  • Güler S; Endocrinology and Metabolism Disease, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Horm Metab Res ; 47(9): 652-5, 2015 Aug.
Article in En | MEDLINE | ID: mdl-25750077
The aim of this study was to investigate atherosclerotic risk markers in women with clinically nonfunctioning pituitary adenomas (CNFAs). Records of 47 women with CNFAs and 73 healthy women who were treated as outpatients between January 2010 and March 2014 were evaluated retrospectively. All study data were obtained from file records. Lipid parameters, mean platelet volume (MPV), total testosterone (TT), androstenedione (AS), and dehydroepiandrostenedione sulfate (DHEAS) were recorded. Insulin resistance (IR) was calculated with homeostatic model assessment-insulin resistance (HOMA-IR). Among the atherosclerotic risk markers, the HOMA-IR and AS levels were higher in patients with CNFAs than in healthy subjects (p=0.003, p=0.021, respectively). A positive correlation between AS and insulin/HOMA-IR levels was found among the metabolic parameters in the patients with CNFAs (p=0.001, r=0.550, p=0.004, r=0.498, respectively). The data showed that patients with CNFAs had high atherosclerotic risk markers such as insulin resistance and hyperandrogenemia. Insulin resistance may also cause hyperandrogenemia in patients with CNFAs.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Pituitary Neoplasms / Insulin Resistance / Adenoma / Hyperandrogenism / Atherosclerosis Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: Horm Metab Res Year: 2015 Type: Article Affiliation country: Turkey

Full text: 1 Database: MEDLINE Main subject: Pituitary Neoplasms / Insulin Resistance / Adenoma / Hyperandrogenism / Atherosclerosis Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: Horm Metab Res Year: 2015 Type: Article Affiliation country: Turkey